source
- Versant and Eli Lilly commit $100 million to launch Seawolf Therapeutics, a non-viral gene-therapy startupVersant Ventures, Eli Lilly and other investors announced a $100 million financing round to create Seawolf Therapeutics, a new company focused on non-viral gene delivery. The startup aims to overc…
- Biogen prepares to unveil results of litifilimab Phase 3 TOPAZ-1 and TOPAZ-2 lupus trials in DecemberBiogen is set to release the readout from two pivotal Phase 3 studies, TOPAZ-1 and TOPAZ-2, evaluating its lupus drug litifilimab. The data are expected in the first half of December and will be th…